Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

The switch of TCA cycle mode determines the fate of pirtobrutinib-tolerant persister cells

View Full Paper
Ask AI
Bookmark
Share

Authors

FYFangfang YanThe University of Texas MD Anderson Cancer Center

Discussion

Loading...

Member takes

Implication

This research reveals therapeutic resistance mechanisms in mantle cell lymphoma, highlighting the implications of DTP cells and metabolic reprogramming.

Key Points

  • To investigate the mechanisms underlying pirtobrutinib-tolerant persister cells in mantle cell lymphoma.
  • Developed a DTP cell line model using Mino-VEN-R and JeKo-1-IBN-R MCL cells.
  • Employed RNA sequencing to analyze gene expression changes.
  • Conducted metabolite profiling using mass spectrometry.
  • Measured oxygen consumption with a Seahorse analyzer.
  • Validated findings in patient-derived organoid and xenograft models.
  • Identified Giant cells that indicate a drug-tolerant persister state in response to pirtobrutinib.
  • Observed a shift between anabolic and catabolic modes of the TCA cycle in DTP cells.
  • Noted the presence of DTP cells correlating with therapy resistance in MCL patients.
  • Highlighted the importance of acetyl-CoA and ATP-citrate lyase in metabolic reprogramming of DTP cells.

Cite This Study

Fangfang Yan (2025) studied this question.

synapsesocial.com/papers/69362f6e4fa91c937236e0dfhttps://doi.org/10.1182/blood-2025-330
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Abstract A018: EMT-like reprogramming defines drug-tolerant persister cell plasticity in mantle cell lymphoma2026
  2. 2Abstract 392: EMT-like reprogramming drives drug-tolerant persister cell plasticity in mantle cell lymphoma via ribosome biogenesis.2026
  3. 3Abstract 7047: Characterization of TKI-induced drug-tolerant persister cells from patient-derived cell lines.2026
  4. 4Dissecting Pirtobrutinib Resistance in Mantle Cell Lymphoma Through Single‐Cell Multi‐Omics2026
  5. 5Shared mechanisms of resistance to zanubrutinib and ibrutinib via EGR1 and DNMT3A in mantle cell lymphoma2025